Class information for: |
Basic class information |
Class id | #P | Avg. number of references |
Database coverage of references |
---|---|---|---|
13608 | 825 | 39.5 | 86% |
Hierarchy of classes |
The table includes all classes above and classes immediately below the current class. |
Cluster id | Level | Cluster label | #P |
---|---|---|---|
0 | 4 | BIOCHEMISTRY & MOLECULAR BIOLOGY//CELL BIOLOGY//ONCOLOGY | 4064930 |
171 | 3 | MONASCUS//CITRININ//MONASCUS PURPUREUS | 58457 |
419 | 2 | STATINS//EZETIMIBE//SIMVASTATIN | 16502 |
13608 | 1 | EZETIMIBE//NPC1L1//CHOLESTEROL ABSORPTION INHIBITOR | 825 |
Terms with highest relevance score |
rank | Term | termType | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|---|
1 | EZETIMIBE | authKW | 5779091 | 42% | 45% | 349 |
2 | NPC1L1 | authKW | 750389 | 5% | 48% | 42 |
3 | CHOLESTEROL ABSORPTION INHIBITOR | authKW | 644795 | 3% | 62% | 28 |
4 | NIEMANN PICK C1 LIKE 1 | authKW | 448604 | 2% | 61% | 20 |
5 | CHOLESTEROL ABSORPTION | authKW | 321194 | 6% | 17% | 50 |
6 | EZETIMIBE SIMVASTATIN | authKW | 197387 | 1% | 67% | 8 |
7 | EZETIMIBE SIMVASTATIN COMBINATION | authKW | 185056 | 1% | 100% | 5 |
8 | CHOLESTEROL ABSORPTION INHIBITION | authKW | 182202 | 1% | 62% | 8 |
9 | EARLY CLIN EXPT MED | address | 139497 | 1% | 54% | 7 |
10 | INTESTINAL CHOLESTEROL ABSORPTION | authKW | 119377 | 1% | 32% | 10 |
Web of Science journal categories |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | Cardiac & Cardiovascular System | 2515 | 22% | 0% | 185 |
2 | Pharmacology & Pharmacy | 1183 | 24% | 0% | 196 |
3 | Peripheral Vascular Diseases | 1043 | 11% | 0% | 91 |
4 | Medicine, General & Internal | 746 | 15% | 0% | 125 |
5 | Endocrinology & Metabolism | 309 | 9% | 0% | 71 |
6 | Medicine, Research & Experimental | 182 | 7% | 0% | 55 |
7 | Biochemistry & Molecular Biology | 176 | 16% | 0% | 135 |
8 | Nutrition & Dietetics | 156 | 4% | 0% | 35 |
9 | Gastroenterology & Hepatology | 123 | 4% | 0% | 37 |
10 | Transplantation | 45 | 2% | 0% | 16 |
Address terms |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | EARLY CLIN EXPT MED | 139497 | 1% | 54% | 7 |
2 | RECH CLIN POLYCLIN | 74022 | 0% | 100% | 2 |
3 | SECT LIPID SCI | 67144 | 2% | 13% | 14 |
4 | FEDERAT PUBL SERV PERSONNEL MUTUAL ASSOC | 41634 | 0% | 38% | 3 |
5 | AFFILIATED BOAI HOSP | 37011 | 0% | 100% | 1 |
6 | AREA PREVENC REHABIL CARDIACA | 37011 | 0% | 100% | 1 |
7 | ARTEROSCLEROSIS | 37011 | 0% | 100% | 1 |
8 | ASKLEPIOS HOSP ST GEORG | 37011 | 0% | 100% | 1 |
9 | ATLANTA VA MED 119 | 37011 | 0% | 100% | 1 |
10 | ATLANTIC MULTIORGAN TRANSPLANTAT PROGRAM | 37011 | 0% | 100% | 1 |
Journals |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | JOURNAL OF CLINICAL LIPIDOLOGY | 18414 | 2% | 3% | 18 |
2 | LIPIDS IN HEALTH AND DISEASE | 9778 | 2% | 1% | 20 |
3 | CURRENT MEDICAL RESEARCH AND OPINION | 8474 | 4% | 1% | 32 |
4 | JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS | 6478 | 2% | 1% | 14 |
5 | INTERNATIONAL JOURNAL OF CLINICAL PRACTICE | 4288 | 3% | 1% | 22 |
6 | JOURNAL OF LIPID RESEARCH | 4139 | 4% | 0% | 31 |
7 | ATHEROSCLEROSIS SUPPLEMENTS | 3331 | 1% | 2% | 5 |
8 | ATHEROSCLEROSIS | 2696 | 3% | 0% | 28 |
9 | CURRENT OPINION IN LIPIDOLOGY | 2246 | 1% | 1% | 9 |
10 | AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS | 2188 | 1% | 1% | 5 |
Author Key Words |
Core articles |
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c: (1) Number of references referring to publications in the class. (2) Share of total number of active references referring to publications in the class. (3) Age of the article. New articles get higher score than old articles. (4) Citation rate, normalized to year. |
Rank | Reference | # ref. in cl. |
Shr. of ref. in cl. |
Citations |
---|---|---|---|---|
1 | DAVIS, HR , TERSHAKOVEC, AM , TOMASSINI, JE , MUSLINER, T , (2011) INTESTINAL STEROL TRANSPORTERS AND CHOLESTEROL ABSORPTION INHIBITION.CURRENT OPINION IN LIPIDOLOGY. VOL. 22. ISSUE 6. P. 467 -478 | 73 | 82% | 9 |
2 | PIRILLO, A , CATAPANO, AL , NORATA, GD , (2016) NIEMANN-PICK C1-LIKE 1 (NPC1L1) INHIBITION AND CARDIOVASCULAR DISEASES.CURRENT MEDICINAL CHEMISTRY. VOL. 23. ISSUE 10. P. 983 -999 | 70 | 63% | 1 |
3 | TOTH, PP , CATAPANO, A , TOMASSINI, JE , TERSHAKOVEC, AM , (2010) UPDATE ON THE EFFICACY AND SAFETY OF COMBINATION EZETIMIBE PLUS STATIN THERAPY.CLINICAL LIPIDOLOGY. VOL. 5. ISSUE 5. P. 655 -684 | 88 | 59% | 4 |
4 | GAZI, IF , MIKHAILIDIS, DP , (2006) NON-LOW-DENSITY LIPOPROTEIN CHOLESTEROL-ASSOCIATED ACTIONS OF EZETIMIBE: AN OVERVIEW.EXPERT OPINION ON THERAPEUTIC TARGETS. VOL. 10. ISSUE 6. P. 851-866 | 83 | 62% | 22 |
5 | LIOUDAKI, E , GANOTAKIS, ES , MIKHAILIDIS, DP , (2011) EZETIMIBE; MORE THAN A LOW DENSITY LIPOPROTEIN CHOLESTEROL LOWERING DRUG? AN UPDATE AFTER 4 YEARS.CURRENT VASCULAR PHARMACOLOGY. VOL. 9. ISSUE 1. P. 62 -86 | 95 | 45% | 23 |
6 | KATSIKI, N , THEOCHARIDOU, E , KARAGIANNIS, A , ATHYROS, VG , MIKHAILIDIS, DP , (2013) EZETIMIBE THERAPY FOR DYSLIPIDEMIA: AN UPDATE.CURRENT PHARMACEUTICAL DESIGN. VOL. 19. ISSUE 17. P. 3107-3114 | 74 | 55% | 14 |
7 | JIA, L , BETTERS, JL , YU, LQ , (2011) NIEMANN-PICK C1-LIKE 1 (NPC1L1) PROTEIN IN INTESTINAL AND HEPATIC CHOLESTEROL TRANSPORT.ANNUAL REVIEW OF PHYSIOLOGY, VOL 73. VOL. 73. ISSUE . P. 239 -259 | 66 | 50% | 66 |
8 | BETTERS, JL , YU, LQ , (2010) NPC1L1 AND CHOLESTEROL TRANSPORT.FEBS LETTERS. VOL. 584. ISSUE 13. P. 2740 -2747 | 55 | 64% | 42 |
9 | DAVIS, HR , VELTRI, ER , (2007) ZETIA: INHIBITION OF NIEMANN-PICK C1 LIKE 1 (NPC1L1) TO REDUCE INTESTINAL CHOLESTEROL ABSORPTION AND TREAT HYPERLIPIDEMIA.JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS. VOL. 14. ISSUE 3. P. 99 -108 | 38 | 90% | 95 |
10 | KALOGIROU, M , TSIMIHODIMOS, V , ELISAF, M , (2010) PLEIOTROPIC EFFECTS OF EZETIMIBE: DO THEY REALLY EXIST?.EUROPEAN JOURNAL OF PHARMACOLOGY. VOL. 633. ISSUE 1-3. P. 62-70 | 59 | 60% | 25 |
Classes with closest relation at Level 1 |